PRMT7: A Drug Target / Disease Biomarker (G54496)

Target Name: PRMT7

NCBI ID: G54496

PRMT7

PRMT7: A Drug Target / Disease Biomarker

PRMT7, also known as PRT7-1, is a protein that is expressed in various tissues of the body, including the brain, muscle, and heart. It is a key regulator of microRNA (miRNA) levels, which are small non-coding RNAs that play a crucial role in post-transcriptional gene regulation.

Studies have shown that PRMT7 is involved in the regulation of a wide range of cellular processes, including cell growth, differentiation, and stress response. It has also been implicated in a number of diseases, including cancer, neurodegenerative diseases, and cardiovascular disease.

As a drug target, PRMT7 is an attractive target for researchers because of its diverse and complex functions, as well as its potential to modulate a wide range of cellular processes. Many studies have identified potential drug candidates that target PRMT7, and further research is being conducted to determine the efficacy and safety of these compounds.

One of the potential benefits of targeting PRMT7 is its potential to treat a wide range of diseases. For example, PRMT7 has been shown to be involved in the regulation of cellular processes that are disrupted in many diseases, including cancer, neurodegenerative diseases, and cardiovascular disease.

In cancer, PRMT7 has been shown to play a role in the regulation of cell growth, apoptosis (programmed cell death), and angiogenesis (the formation of new blood vessels). It has also been shown to be involved in the regulation of microRNA levels, which are often disrupted in cancer cells.

In neurodegenerative diseases, PRMT7 has been shown to play a role in the regulation of cellular processes that are disrupted in diseases such as Alzheimer's and Parkinson's. It has also been shown to be involved in the regulation of microRNA levels, which are often disrupted in these diseases.

In cardiovascular disease, PRMT7 has been shown to play a role in the regulation of cellular processes that are disrupted in this disease. It has also been shown to be involved in the regulation of microRNA levels, which are often disrupted in cardiovascular disease.

As a drug target, PRMT7 is an attractive target because of its diverse and complex functions, as well as its potential to modulate a wide range of cellular processes. Further research is needed to determine the efficacy and safety of potential drug candidates that target PRMT7.

Protein Name: Protein Arginine Methyltransferase 7

Functions: Arginine methyltransferase that can both catalyze the formation of omega-N monomethylarginine (MMA) and symmetrical dimethylarginine (sDMA), with a preference for the formation of MMA. Specifically mediates the symmetrical dimethylation of arginine residues in the small nuclear ribonucleoproteins Sm D1 (SNRPD1) and Sm D3 (SNRPD3); such methylation being required for the assembly and biogenesis of snRNP core particles. Specifically mediates the symmetric dimethylation of histone H4 'Arg-3' to form H4R3me2s. Plays a role in gene imprinting by being recruited by CTCFL at the H19 imprinted control region (ICR) and methylating histone H4 to form H4R3me2s, possibly leading to recruit DNA methyltransferases at these sites. May also play a role in embryonic stem cell (ESC) pluripotency. Also able to mediate the arginine methylation of histone H2A and myelin basic protein (MBP) in vitro; the relevance of such results is however unclear in vivo

The "PRMT7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PRMT7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets